Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial

Journal:

Journal of Clinical Oncology

Published:

2026-06-02

DOI:

10.1200/jco-26-00788

Affiliations:

25

Authors:

27

Go to article

Institutions	Authors	Share
Incyte, United States of America (USA)	3.000000	0.11
Incyte Biosciences International Sàrl, Switzerland	2.000000	0.07
IRCCS Istituto Oncologico Veneto (IOV), Italy	1.000000	0.04
University Hospitals Coventry and Warwickshire NHS Trust, United Kingdom (UK)	1.000000	0.04
Providence Cancer Institute of Oregon, United States of America (USA)	1.000000	0.04
Kanagawa Cancer Center, Japan	1.000000	0.04
Mayo Clinic Hospital - Phoenix, United States of America (USA)	1.000000	0.04
IRCCS National Cancer Institute (INT) Milan, Italy	1.000000	0.04
University Hospital of Pisa, UNIPI, Italy	1.000000	0.04
Mayo Clinic's Campus in Florida, United States of America (USA)	1.000000	0.04
Virginia Mason Medical Center (Virginia Mason), United States of America (USA)	1.000000	0.04
UCL, United Kingdom (UK)	1.000000	0.04
Maastricht University Medical Center+ (Maastricht UMC+), Netherlands	1.000000	0.04
University of Verona (UNIVR), Italy	1.000000	0.04
Hannover Medical School (MHH), Germany	1.000000	0.04
Amsterdam UMC, Netherlands	1.000000	0.04
Yamaguchi University Hospital (YUH), Yamaguchi University, Japan	1.000000	0.04
San Camillo Forlanini Hospital, Italy	1.000000	0.04
Agostino Gemelli University Polyclinic, Italy	1.000000	0.04
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.04
Investigación Sanitaria del Hospital Gregorio Marañón (IISGM), Spain	1.000000	0.04
Mayo Clinic, United States of America (USA)	1.000000	0.04
Karolinska University Hospital, Sweden	1.000000	0.04
Humanitas University, Italy	0.500000	0.02
IRCCS Humanitas Research Hospital, Italy	0.500000	0.02